CUS0 Stock Overview A biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Curis Historical stock prices Current Share Price US$2.94 52 Week High US$15.50 52 Week Low US$2.94 Beta 3.36 1 Month Change -25.76% 3 Month Change -40.73% 1 Year Change n/a 3 Year Change -96.68% 5 Year Change -89.11% Change since IPO -99.84%
Recent News & Updates
Curis, Inc. Announces Additional Data from Take Aim Leukemia Study Dec 10
Third quarter 2024 earnings released: US$1.70 loss per share (vs US$2.13 loss in 3Q 2023) Nov 17
Curis, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Nov 07
New minor risk - Shareholder dilution Nov 01 Curis, Inc. has filed a Follow-on Equity Offering in the amount of $12.099999 million. Oct 30
Curis, Inc. has filed a Follow-on Equity Offering in the amount of $12.099999 million. Oct 29
See more updates
Curis, Inc. Announces Additional Data from Take Aim Leukemia Study Dec 10
Third quarter 2024 earnings released: US$1.70 loss per share (vs US$2.13 loss in 3Q 2023) Nov 17
Curis, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Nov 07
New minor risk - Shareholder dilution Nov 01 Curis, Inc. has filed a Follow-on Equity Offering in the amount of $12.099999 million. Oct 30
Curis, Inc. has filed a Follow-on Equity Offering in the amount of $12.099999 million. Oct 29
Second quarter 2024 earnings released: US$2.03 loss per share (vs US$2.47 loss in 2Q 2023) Aug 02
Curis, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 25
Curis, Inc. Announces Additional Data from Take Aim Leukemia Study May 16
New major risk - Revenue and earnings growth May 13
First quarter 2024 earnings released: US$2.05 loss per share (vs US$2.39 loss in 1Q 2023) May 08
Curis, Inc. to Report Q1, 2024 Results on May 07, 2024 May 01
Curis, Inc., Annual General Meeting, May 21, 2024 Apr 11
New major risk - Revenue and earnings growth Mar 08
Full year 2023 earnings released: US$8.96 loss per share (vs US$12.14 loss in FY 2022) Feb 09 Curis, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Feb 09
Curis, Inc. to Report Q4, 2023 Results on Feb 08, 2024 Feb 02
Curis, Inc. Announces Initial Combination Study Data from Its Take Aim Lymphoma Study Dec 12
Curis, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 27
Second quarter 2023 earnings released: US$0.12 loss per share (vs US$0.17 loss in 2Q 2022) Aug 05
Curis, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 29
U.S. Food and Drug Administration Removes Partial Clinical Hold on Curis, Inc.'s TakeAim Leukemia Study RP2D Established At 300 Mg BID Jul 07
First quarter 2023 earnings released: US$0.12 loss per share (vs US$0.18 loss in 1Q 2022) May 07
Full year 2022 earnings released: US$0.61 loss per share (vs US$0.50 loss in FY 2021) Mar 15
Curis, Inc. Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS Dec 13
Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.12 loss in 3Q 2021) Nov 11
Curis, Inc. to Report Q3, 2022 Results on Nov 09, 2022 Nov 03
Curis Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Oct 27
Curis, Inc. Elects Anne E. Borgman as Class I Director Oct 16
Curis, Inc. Announces Resignation of Lori A. Kunkel, M.D. from the Board of Directors, Effective September 30, 2022 Sep 23
Curis, Inc. Announces That the U.S. Food and Drug Administration (FDA) Has Notified Curis That It May Resume Enrollment of Additional Patients in the Monotherapy Phase of the TakeAim Leukemia Study Aug 31
FDA Lifts Partial Clinical Hold on the Takeaim Lymphoma Study of Emavusertib of Curis, Inc Aug 19
Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.12 loss in 2Q 2021) Aug 06
Curis, Inc. Appoints Diantha Duvall as Chief Financial Officer, Treasurer, Assistant Secretary, Principal Financial Officer and Principal Accounting Officer of the Company Effective as of August 5, 2022 Aug 06
Curis, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 29 Curis, Inc. Announces Resignation of William Steinkrauss as Chief Administrative Officer, Effective from August 5, 2022 Curis, Inc.(NasdaqGM:CRIS) dropped from Russell 3000E Growth Index
Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO) Jun 05
First quarter 2022 earnings released: US$0.18 loss per share (vs US$0.11 loss in 1Q 2021) May 06
Curis, Inc., Annual General Meeting, May 26, 2022 Apr 14
Curis, Inc. Announces FDA Partial Clinical Hold for on the Company’s Takeaim Lymphoma Phase 1/2 Study Apr 12
Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948) Apr 05 Curis, Inc. Announces Gastroenterology Publication of Encouraging Preclinical Data of Emavusertib in Pancreatic Cancers Mar 10
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 26
Curis, Inc. to Report Q4, 2021 Results on Feb 24, 2022 Feb 18
Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and MDS; and Initial Clinical Data from Phase 1 Study of CI-8993 in Patients with Relapsed or Refractory Solid Tumors Jan 07
Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.11 loss in 3Q 2020) Nov 10
Insufficient new directors Nov 01
Insufficient new directors Oct 02
Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.17 loss in 2Q 2020) Aug 05
Curis Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes Jun 12
First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.28 loss in 1Q 2020) May 14
Curis Receives U.S. Food and Drug Administration Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS Apr 20
Full year 2020 earnings released: US$0.61 loss per share (vs US$0.97 loss in FY 2019) Mar 18
Curis, Inc. to Report Q4, 2020 Results on Mar 16, 2021 Mar 10
Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies Feb 10
Curis Announces Initiation of Investigator-Sponsored Phase 2 Lucas Study of Ca-4948 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes Feb 03
New 90-day high: €7.25 Jan 06
New 90-day high: €6.70 Dec 12
Curis, Inc. has completed a Follow-on Equity Offering in the amount of $147.500001 million. Dec 11
Curis, Inc. Announces Updated Preliminary Data from Ongoing Phase 1 Study of CA-4948 Showing Durable and Dose-Dependent Reductions in Tumor Burden in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma Dec 10
New 90-day high: €1.17 Nov 25
Third quarter 2020 earnings released: US$0.11 loss per share Nov 12
Curis, Inc. to Report Q3, 2020 Results on Nov 10, 2020 Nov 05
Curi Announces Appointment of Jason Sandner as its Next Chief Executive Officer, Effective July 1, 2021 Oct 16
Curis, Inc. Announces Abstract for CI-8993 Accepted for Presentation At the Society for Immunotherapy of Cancer's 35th Anniversary Annual Meeting Oct 15
New 90-day low - €0.74 Sep 07
First half earnings released Aug 06
Curis, Inc. has completed a Follow-on Equity Offering in the amount of $17.5 million. Aug 06
Curis, Inc. to Report Q2, 2020 Results on Aug 04, 2020 Jul 31 Shareholder Returns CUS0 DE Biotechs DE Market 7D -12.5% -3.5% -2.0% 1Y n/a -14.7% 6.9%
See full shareholder returns
Return vs Market: Insufficient data to determine how CUS0 performed against the German Market .
Price Volatility Is CUS0's price volatile compared to industry and market? CUS0 volatility CUS0 Average Weekly Movement 10.0% Biotechs Industry Average Movement 6.8% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: CUS0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CUS0's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3.
Show more Curis, Inc. Fundamentals Summary How do Curis's earnings and revenue compare to its market cap? CUS0 fundamental statistics Market cap €24.99m Earnings (TTM ) -€43.59m Revenue (TTM ) €9.83m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CUS0 income statement (TTM ) Revenue US$10.26m Cost of Revenue US$39.74m Gross Profit -US$29.48m Other Expenses US$16.00m Earnings -US$45.48m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -5.37 Gross Margin -287.37% Net Profit Margin -443.35% Debt/Equity Ratio -412.0%
How did CUS0 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 20:25 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Curis, Inc. is covered by 27 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Brian Skorney Baird James Birchenough BMO Capital Markets Equity Research Brian Skorney Brean Capital
Show 24 more analysts 
